State Street
ELVN icon

State Street’s Enliven Therapeutics ELVN Stock Holding History

State Street’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.6M Buy
1,213,616
+122,510
+11% +$5.2M ﹤0.01% 1730
2026
Q1 		$42.8M Buy
1,091,106
+38,244
+4% +$1.06M ﹤0.01% 1825
2025
Q4 		$16.2M Buy
1,052,862
+87,725
+9% +$1.75M ﹤0.01% 2374
2025
Q3 		$19.8M Buy
965,137
+148,895
+18% +$3M ﹤0.01% 2255
2025
Q2 		$16.4M Buy
816,242
+35,340
+5% +$669K ﹤0.01% 2299
2025
Q1 		$15.4M Sell
780,902
-20,930
-3% -$450K ﹤0.01% 2276
2024
Q4 		$18M Buy
801,832
+55,888
+7% +$1.45M ﹤0.01% 2280
2024
Q3 		$19.1M Buy
745,944
+21,018
+3% +$487K ﹤0.01% 2236
2024
Q2 		$16.9M Buy
724,926
+233,078
+47% +$4.91M ﹤0.01% 2251
2024
Q1 		$8.65M Buy
491,848
+7,333
+2% +$113K ﹤0.01% 2668
2023
Q4 		$6.71M Buy
484,515
+13,663
+3% +$167K ﹤0.01% 2798
2023
Q3 		$6.43M Buy
470,852
+4,601
+1% +$77.5K ﹤0.01% 2811
2023
Q2 		$9.52M Buy
466,251
+456,827
+4,847% +$9.23M ﹤0.01% 2673
2023
Q1 		$206K Sell
9,424
-1
-0% -$20 ﹤0.01% 4068
2022
Q4 		$154K Buy
9,425
+4,125
+78% +$65.9K ﹤0.01% 4216
2022
Q3 		$48K Hold
5,300
– – ﹤0.01% 4665
2022
Q2 		$26K Hold
5,300
– – ﹤0.01% 4838
2022
Q1 		$40K Hold
5,300
– – ﹤0.01% 4833
2021
Q4 		$48K Hold
5,300
– – ﹤0.01% 4707
2021
Q3 		$86K Hold
5,300
– – ﹤0.01% 4577
2021
Q2 		$167K Sell
5,300
-22,346
-81% -$693K ﹤0.01% 4253
2021
Q1 		$933K Buy
27,646
+1,320
+5% +$67.1K ﹤0.01% 3636
2020
Q4 		$2.32M Buy
26,326
+10,323
+65% +$866K ﹤0.01% 3304
2020
Q3 		$1.3M Buy
16,003
+1,927
+14% +$174K ﹤0.01% 3358
2020
Q2 		$1.56M Buy
+14,076
New +$1.58M ﹤0.01% 3280

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

State Street's ELVN Position: Q2 2026 in Review

State Street increased its Enliven Therapeutics (ELVN) stake by 11% in Q2 2026, buying an estimated $5.2M and bringing the position to 1,213,616 shares worth $61.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

State Street first reported a position in ELVN in Q2 2020 and has held it in 25 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • State Street held 1,213,616 shares of Enliven Therapeutics worth $61.6M as of Q2 2026.
  • State Street bought 122,510 Enliven Therapeutics shares in Q2 2026, an estimated $5.2M.
  • Enliven Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1730 holding.
  • State Street first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.